Recent Articles

• 
  Biopharma

  Korea United Pharma Normalizes Supply of DTI Injection

  Korea United Pharm Sejong Plant 2. Provided by Korea United Pharm The production line for an essential anticancer drug, which had faced the risk of supply interruption, is being restarted with comprehensive administrative support from the health authorities. Supply of DTI Injection 200 mg from Korea

  2026.06.15
• 
  AI Healthcare

  AI Flags Possible Heart Attack, Recommends Hospital

  At the “Emergency Medical Artificial Intelligence Transformation (AX) Technology Demonstration” held at Kyungpook National University Hospital in Daegu on the 12th, when a virtual emergency patient told a paramedic “My chest hurts,” the AI automatically entered “chest pain” as the symptom and prepar

  2026.06.15
• 
  Medical / Drug Development

  Gene Editing Nears Reality; Korean Therapies in Five Years

  In an interview conducted on the 6th of last month, Bae Sang-soo, professor at Seoul National University College of Medicine, cited the development of delivery systems and the maturation of the industrial ecosystem as key tasks for the advancement of gene-editing technology in Korea. Professor Bae s

  2026.06.15
• 
  MedTech

  Ultra-thin Pipes Top KRW 10 Million per Meter

  On 8 June, Enventric Co-CEO Min Ji-young explains how the company’s pulsed field ablation catheter works at its office in Guro District, Seoul. Photo by reporter Heo Jin-seok, jameshur@donga.com The most critical devices that enter the inside of the heart and cerebral blood vessels in domestic opera

  2026.06.13
• 
  Biotech

  Ildong Bioscience Showcases Sleep Microbiome Research in North America

  Idong Bioscience booth at Probiota Americas 2026. Provided by Idong Bioscience Idong Bioscience, a health functional food subsidiary of Idong Pharmaceutical Group, announced on the 12th that it participated in “Probiota Americas 2026” held in Vancouver, Canada, and presented its latest research achi

  2026.06.12
• 
  Pharmaceutical R&D

  Celltrion Anticancer CT-P72 Shows Promise for Solid Tumors

  Provided by Celltrion Celltrion announced on the 12th that it has confirmed the potential to expand indications to various solid tumors for its next-generation multi-specific antibody new drug “CT-P72 (ABP-102),” based on its excellent efficacy and tolerability. The research results were unveiled on

  2026.06.12
• 
  Medical / Research

  Korean Team First to Map Assembly of Disease-Blocking Protein Complex

  Kim V. Narry, director of the RNA Research Center at the Institute for Basic Science (IBS). Provided by IBS The prospects are improving for more precise design of ribonucleic acid (RNA) therapeutics to treat intractable diseases caused by gene overexpression, following the elucidation of the formati

  2026.06.12
• 
  AI Healthcare

  SNU Professor Lee Jaesung Wins First Asian Hoffman Memorial Prize

  Lee Jae-sung, professor at Seoul National University College of Medicine. Courtesy of SNU On the 11th, Seoul National University (SNU) announced that Professor Lee Jae-sung of SNU College of Medicine and the Interdisciplinary Program for Advanced Convergence has been selected as the recipient of the

  2026.06.12
• 
  Vaccine

  GC Pharma Unveils mRNA Platform, Preps COVID Vaccine Trial

  Panoramic view of GC Green Cross headquarters. Provided by GC Green Cross GC Green Cross is pushing ahead with the development of a COVID-19 vaccine based on its self-developed mRNA-LNP platform. The company is targeting submission of a phase 2 clinical trial plan in the second half of this year.GC

  2026.06.11
• 
  DTx / Platform

  IlDong Pharma, Welt Partner on Digital Convergence Drug

  IlDong Pharmaceutical CEOs Yoon Woong-seop (right) and Lee Jae-joon (left) pose for a commemorative photo after signing a business agreement with Kang Sung-ji, CEO of WELT. IlDong Pharmaceutical is promoting the development of “digital convergence pharmaceuticals” designed to enhance patients’ medic

  2026.06.11